Ownership history in TWO SIGMA SECURITIES, LLC Β· 78 quarters on record
This page tracks every 13F SEC filing in which TWO SIGMA SECURITIES, LLC reported a position in REGENERON PHARMACEUTICALS (REGN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π TWO SIGMA SECURITIES, LLC underperformed the S&P 500 by β13.4% annually on this REGN position. Timing score: 40% (31/77 decisions correct). Average cost basis: $469.12. Maximum drawdown during holding period: β49.9%.
β Significantly underperformed the S&P 500 by 13.4% ann.
24 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
31 of 77 add/trim decisions correct
Best entry: $275.54 (2019 Q3) Β· Worst: $1044.19 (2024 Q3)
πͺ Held through 3 major drawdowns (>20%). Diamond-hands conviction.
42 adds Β· 36 trims. Bought during 8 of 15 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.04% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size